Dose-dependent volume loss in subcortical deep grey matter structures after cranial radiotherapy

Introduction

Irradiation of healthy brain tissue can lead to anatomical and functional deficits, a phenomenon known as radiation-induced brain injury. This can lead to a variety of symptoms, with especially cognitive and executional impairments leading to a marked decrease in the patient’s quality of life after radiation therapy (RT) [1,2].

With the advent of high-resolution brain imaging, the interest in morphological changes after RT has increased. The cerebral cortex has been shown to be susceptible to radiation-induced thinning, especially in areas associated with cognitive functioning [3–6]. Thinning rates are found to be dose-dependent, meaning that a higher dose leads to a further diminished cortex. Similarly, diffusion tensor imaging has shown that white matter shows dose-dependent changes in several metrics after RT [7]. Finally, two grey matter structures, the hippocampus [8] and the amygdala [9], show susceptibility to radiation damage, again with higher volume changes with increasing dose. Furthermore, the dose to the hippocampus has been shown to negatively affect neurocognitive outcome after RT [10].

Less is known about the susceptibility to radiation damage of other subcortical grey matter structures, such as the nucleus accumbens, caudate nucleus, globus pallidus, putamen, and thalamus. Atrophy of these deep GM structures is associated with impaired cognitive function in patients with degenerative brain diseases as well as healthy ageing [11–13]. This relation is most pronounced in Alzheimer’s disease, with the volume of all mentioned structures, with the exception of globus pallidus, being associated with cognitive impairment [14–16]. Globus pallidus volume in its turn is associated with cognitive outcomes in Huntington’s disease and age-related cognitive impairments [17,18].

Volume changes in these structures are associated with cognitive outcomes, and the cause of post-RT cognitive decline needs to be elucidated. Therefore, we examined the relation between post-RT subcortical GM volume changes and RT dose.

Methods

Image processing

A graphical overview of the image processing pipeline is shown in Figure 1. All imaging data was processed with Statistical Parametric Mapping (SPM12, v7487)[19] Computational Anatomy Toolbox (CAT12.6 r1450) [20] and in-house algorithms developed in MATLAB (Mathworks, Natick, Massachusetts, USA).

• Download figure
• Open in new tab

Figure 1

Pipeline of image processing. Left column: dose (gradient) and PTV (red shading) are extracted from CT. Middle and right column: organ volume is estimated from processed MRI. After censoring organs within PTV, applied dose is related to the change in organ volume.

Image processing was done in concordance to our own previously published criteria [3], amended for the current research question. More detailed image processing methods can be found in our previous work [4].

In brief, the cropped CT image with the associated dose and planning target volume (PTV) maps were registered to the T1 MR images, resulting in the CT image and the MRIs being in the same space. Next, the rigidly coregistered T1s were processed with CAT12’s segmentation pipeline.

Deep GM structure volumes were estimated with CAT12 using the fully automated volume estimation method using the labels from the Neuromorphometrics atlas (Neuromorphometrics Inc., Somerville, Massachusetts, USA). The following structures were examined: amygdala, nucleus accumbens, caudate nucleus, hippocampus, globus pallidus, putamen, and thalamus. Figure 2 shows the anatomical location of the structures on axial T1 MRI, as well as in a 3D rendering.

• Download figure
• Open in new tab

Figure 2

A 3D rendering and axial MR images showing the subcortical grey matter structures being analysed.

The within-subject difference in deep GM volume was calculated by subtracting the baseline and the follow-up volume. In every subject the deep GM organs included in the PTV were censored from analysis, to avoid spurious volume-dose relations originating from segmentation errors due to damage around the tumour. If the residual damage (e.g. oedema, surgical scarring, tumour bed) extended beyond the PTV in either the baseline or the follow-up images, then the affected subject was removed from the analysis.

Results

Subcortical GM volume

Significant dose-dependent volume loss was observed in all examined structures, except for caudate nucleus. Rates of volume loss vary from 0.16 to 1.37% per Gy (corresponding to 4.9% and 41.2% per 30 Gy), and are shown for all structures in Table 2. Scatterplots of the organs in which a significant relation between RT dose and volume loss was seen are shown in Figure 3.

View this table:

• View inline
• View popup
• Download powerpoint

Table 2

Dose-dependent changes in volumes of subcortical GM structures

• Download figure
• Open in new tab

Figure 3

Scatterplots showing the relation between mean RT dose and volume loss in the structures where this was significant, with fitted linear regression lines.

The sensitivity analysis done to assess the effect of chemotherapy on this relation is shown in Supplementary Table 1. It did not result in a change in direction or effect size of the results, and chemotherapy administration did not significantly affect GM volume.

Hippocampal volume nomograms

In this cohort 22 patients were within the age range of 52 to 72, and thus were entered into the nomograms from the UK Biobank, which are shown in Figure 4. All patients show an increase in hippocampal age, with a median increase of eleven years (range 2 - 20 years). Accordingly, the percentile within the nomogram dropped for all patients, meaning that their hippocampal volume shows a decrease compared to their peers of the same age.

• Download figure
• Open in new tab

Figure 4

Change in patients’ hippocampal age (left) and position within the nomogram (right) based on the UK Biobank [24].*Age within the nomogram has a maximum of 72.

Discussion

We have found that all subcortical deep grey matter structures, with the exception of caudate nucleus, show dose-dependent volume loss after RT. For the hippocampus, we have also shown that, based on data from the normal population, its volume-based age increases with up to twenty years during the year post-radiation.

The amygdala and hippocampus have shown to be susceptible to radiation damage in previous studies. Seibert et al. [8] studied MRIs before and one year after RT of 52 patients with primary brain tumours. Automatic segmentation of the hippocampus was followed by relating the difference in volume to the mean dose received. They found a significant correlation with a Pearson correlation coefficient of −0.24. Furthermore, they found that the hippocampus showed significant volume loss after high-dose RT (defined as >40 Gy). This in contrast to low-dose (<10 Gy), which showed no significant relation with post-RT volume. A linear mixed-effects model resulted in a volume loss rate of 0.13%/Gy, which is similar to our observed loss rate of 0.16%/Gy.

The volumetric changes in the amygdala after RT have been studied by Huynh-Le et al. [9] in the same cohort of 52 patients. A significant Pearson correlation of −0.28 was found for amygdala volume and mean dose, with a volume loss rate of 0.17%/Gy. The difference to our findings of a correlation coefficient of −0.52 and volume loss rate of 0.30%/Gy could be explained by the difference in censoring method. They censored amygdalae manually when a visual inspection deemed the segmentation to be poor, whereas we censored more strictly by censoring any organ within the PTV. This meant that they have more data points within higher dose regions, which could have led to a different slope and correlation coefficient.

A link between the volumes of these structures and cognitive outcomes has been thoroughly examined in other brain diseases. Particularly In Alzheimer’s disease, available evidence points towards a strong relation between subcortical GM structures and cognitive impairments for each of the structures we studied except for globus pallidus [14–16]. Furthermore, cognitive impairments in Parkinson’s disease [26,27], multiple sclerosis [28], Huntington disease [17], as well as in normal ageing [12], have been linked with the volume of at least one of the subcortical GM structures. Supplementary Table 2 gives an overview of some available literature per GM structure.

The effect of hippocampal dose and neurocognitive outcomes was first shown by Gondi et al. [10]. They showed that radiation dose of >7.3 Gy to 40% of the bilateral hippocampi was associated with an impairment in Wechsler Memory Scale-III Word List delayed recall. The same group conducted phase II and phase III trials, the latter studying the effect of whole brain radiotherapy (WBRT) with or without hippocampal avoidance [29,30]. They found hippocampal avoidance WBRT, in combination with the N-methyl-D-aspartate inhibitor memantine, preserves cognitive function while maintaining the same overall and progression-free survival.

In this study the investigation of caudate nucleus volume change in relation to the local dose was inconclusive. One explanation could be that the quality of the segmentation is region dependent. While generally the segmentations of SPM/CAT12 is highly reproducible [31–33], among the investigated regions caudate requires the largest sample size to achieve the same statistical power as compared to other regions [34]. The caudate nucleus shares a relatively large interface with the ventricles (Figure 2), making it highly susceptible to partial voluming artefacts, which may lead to errors in segmentation.

Our results challenge us to reconsider the currently used sparing strategies in radiation treatment of brain tumours. Presently, hippocampal sparing RT has been adopted in several institutions. However, sparing the dose in the hippocampus leads to higher doses in surrounding cerebral tissues, which we have shown to be susceptible to radiation-induced damage as well [35]. Future research has to focus on the relation between clinical outcomes (including cognitive and motor function) and morphologic changes, both in the entire brain and in selected structures. This way we can conclusively say which structures should be avoided in RT planning to prevent radiation-induced damage. Specific sparing of healthy brain is possible with novel techniques such as proton therapy and VMAT. This could lead to improved cognition and quality of life in patients undergoing treatment for brain tumours.

There are several limitations to this study. Firstly, we have a relatively limited sample size due to the strenuous inclusion criteria. However, these criteria ensure that the quality of the imaging used in analysis are optimal, meaning more reliable and replicable results. The censoring of the PTV also means exclusion of several subcortical GM structures, but this again is to ensure reliable automated measurements. Attempts could have been made to manually delineate these structures, but this would have added an extra variable to the dose/volume relation (manual vs automatic segmentation in high and lower dose, respectively). Additionally, it is unclear which method gives the most reliable results in patients who underwent RT. In previous works [36–38], the automated segmentation method used in the current study was rigorously compared to manual segmentation of subjects’ T1 MRI data as well as brain phantoms representing a wide range of settings (noise, artefacts, etc.). It was found that CAT12 performed on a comparable level versus manual segmentation in healthy subjects as well as patients with ischemic stroke or temporal lobe epilepsy, suggesting it is reliable for segmentation in RT patients. Another consideration is that susceptibility to radiation-induced volume loss of brain tissue might differ between patients. As each patient provides multiple organs for examination, this could have impacted the found results. We could not correct for this in the current study, as our sample size limited our ability to apply multilevel modelling of the dose/volume relation.

Secondly, the patients in our cohort did not only undergo RT. Many also received chemotherapy, which has been linked to cerebral changes in non-neurological malignancies [39,40]. Our analysis focussed on the association between RT dose and volume, and by relating these two factors to each other we have limited the effect of chemotherapy as much as possible. Furthermore, a sensitivity analysis including chemotherapy in the model did not give different results, suggesting its role is limited.

Finally, the absence of neurocognitive outcome data from this cohort means we cannot yet give clinical recommendations on which organs to spare.

In conclusion, subcortical grey matter structures show susceptibility to dose-dependent volume loss after radiotherapy. If neurocognitive outcomes are related to this phenomenon, current RT strategies need to be revised, in order to improve patients’ quality of life after cancer treatment.